WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be ...

Repligen reported year-on-year revenue growth of 14% for the quarter and 16% for the year. Full-year adjusted EBITDA margin was 19%, or 50 basis points better than last year. Management's guidance for ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Tuesday reported fourth-quarter earnings of $13.3 million. The Waltham, Massachusetts-based company said it had net income of 23 ...

Repligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Call Transcript April 29, 2025 Repligen Corporation beats earnings expectations. Reported EPS is $0.39, expectations were $0.35. Operator: Good day, ...

Repligen Corporation (NASDAQ:RGEN) is one of the best mid-cap growth stocks to buy right now. On January 16, UBS raised the firm’s price target on Repligen to $200 from $190, while maintaining a Buy ...

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be ...

I'm wrapping up the quarter for a lot of these sessions as a kickoff. For Repligen, it was a good quarter. It was 18% organic growth. Each of the key product areas was up double digits. Op margins ...

WALTHAM, Mass.(AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Tuesday reported third-quarter net income of $14.9 million. On a per-share basis, the Waltham, Massachusetts-based company said it ...